HUM, AFLB.OB, & AVEO: Humana reported a diluted earnings per common share (EPS) of $2.00

HUM, AFLB.OB, & AVEO: Humana reported a diluted earnings per common share (EPS) of $2.00
Spread the Word
Listed Under

A5 Laboratories Inc
Analytical And Development Services
Bioactif Inc
Contract Research
Emerging Stock

• Stocks


Aug. 3, 2010 - PRLog -- Humana Inc. Common Stock

Humana Inc., headquartered in Louisville, Kentucky, is one of the nation's largest publicly traded health and supplemental benefits companies, with approximately 10.4 million medical members and approximately 7.2 million specialty-benefit members. Humana is a full-service benefits solutions company, offering a wide array of health and supplemental benefit plans for employer groups, government programs and individuals.

Humana has recently reported diluted earnings per common share (EPS) for the quarter ended June 30, 2010 (2Q10) of $2.00, above management’s guidance of $1.65 to $1.70. The 2Q10 results compared to EPS of $1.67 for the quarter ended June 30, 2009 (2Q09). For the six months ended June 30, 2010 (1H10) the company reported $3.52 in EPS compared to $2.89 for the six months ended June 30, 2009 (1H09).



A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.

A5 Laboratories, Inc. has recently reported that it has signed an analytical services contract with BioActif Inc . of Blainville, Quebec. Upon obtaining health Canada laboratory establishment license, A5 Labs will provide a comprehensive analytical and development services for BioActif . These services will include method development, raw materials and finished goods testing as well as stability studies.

A5 Laboratories Inc. is pleased to provide an update on the company's business development activities for the month of July.

On July 5, 2010 ALFB.ob closed the acquisition of the Contract Research Organization (CRO) and laboratory assets as well as intellectual property relating to a method for the production of interferon products. Subsequently, the company entered into agreements with two CRO customers to provide a comprehensive range of services.

Most recently A5 Labs submitted a provisional patent application to protect its technology for the production of interferon-based products. A5 Labs' lead product, VI-1718, has potential broad based applications for the treatment of certain types of cancer as well as multiple sclerosis and viral infections.

Most recently A5 Labs submitted a provisional patent application to protect its technology for the production of interferon-based products.

(Source: CLICK HERE)


AVEO Pharmaceuticals, Inc. (AVEO)

AVEO Pharmaceuticals blends a proprietary cancer biology platform with drug development and commercial expertise to discover and develop targeted cancer therapeutics. The company's lead product, tivozanib, is an oral, triple VEGF receptor inhibitor with a highly differentiated profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEO's proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development and has provided a discovery engine for high-value targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR.

AVEO is a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Murray Robinson, Ph.D., senior vice president, translational medicine, is scheduled to present at the Cancer Stem Cells & The Tumor Microenvironment Conference, part of IBC's Drug Discovery & Development Week, on Monday, August 2, 2010 at 1:45 p.m. (PDT) at the Hyatt Regency San Francisco Airport in San Francisco.

Dr. Robinson will give a presentation, entitled "Myeloid Resistance Biomarkers for the VEGFR TKI Tivozanib Identified Using Next Generation Tumor Models," that will focus on the utility of AVEO's specific myeloid based multi-gene and IHC resistance biomarkers in assessing the activity of tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2 and 3, in human renal cell carcinoma (RCC).

Sign-Up For Free Stock Alerts At


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has received eight thousand dollars in cash from a third party (Winning Media) for (one) day of advertising for A5 Laboratories Inc. (AFLB.OB)


# # #

Crown Equity Holdings Inc. assists and consults with domestic and foreign companies interested in becoming publicly traded in the U.S. The company designs and manufactures multi-monitor computer systems for financial traders and audio/video professionals.
Source:Blayne Sheffield
Email:*** Email Verified
Tags:A5 Laboratories Inc, Aflb, Analytical And Development Services, Bioactif Inc, Contract Research, Cro, Emerging Stock
Location:United States
Account Email Address Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share